Axsome Therapeutics AXSM Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's total liabilities?
- Axsome Therapeutics (AXSM) reported total liabilities of $659.02M in Q1 2026.
- How has Axsome Therapeutics's total liabilities changed year-over-year?
- Axsome Therapeutics's total liabilities increased by 21.3% year-over-year, from $543.47M to $659.02M.
- What is the long-term trend for Axsome Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Axsome Therapeutics's total liabilities has grown at a 52.7% compound annual growth rate (CAGR), from $72.34M to $601.51M.
- What does total liabilities mean?
- The total amount of money the company owes to all creditors and suppliers.
- How do you interpret total liabilities?
- An increase may indicate higher debt financing or operational expansion, while a decrease suggests debt repayment or reduced operational scale.
- How does total liabilities compare across companies?
- Varies significantly based on capital structure and stage of clinical development compared to other biotech peers.